Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Yuanliang Zhou
Observed name:
Y. Zhou
Institutions:
Shandong Tumor Hospital,
Shandong First Medical University
Observed institutions:
Georgetown University,
Georgetown University Medical Center,
Shandong Tumor Hospital,
Shandong First Medical University,
Georgetown Lombardi Comprehensive Cancer Center
ORCID:
0009-0002-9800-663X
Observed ORCID:
0009-0002-9800-663X
OpenAlex ID:
A5076073211
Potential increased risk of cancer from commonly used medications: an umbrella review of meta-analyses
2013
·
J.P.A. Ioannidis
, Y. Zhou
, et al.
·
Annals of Oncology
·
53
Bevacizumab improved prognosis for advanced EGFR-mutant lung adenocarcinoma with brain metastasis receiving cerebral radiotherapy
2024
·
Yuanliang Zhou
, Jingchao Li
, et al.
·
Clinical & Translational Oncology
·
4
PDF
P2.07-050 Impact of Steroid Use for Immune Related Adverse Events on Outcomes in Non-Small Cell Lung Cancer (NSCLC) Treated with Checkpoint Inhibitors
2017
·
N. Shah
, W. Kelly
, et al.
·
Journal of Thoracic Oncology
·
3
PDF
Survival outcomes of upfront versus delayed craniocerebral radiotherapy in EGFR-mutant NSCLC patients treated with third-generation EGFR-TKIs
2025
·
Guangchuan Deng
, Yuanliang Zhou
, et al.
·
Clinical & Experimental Metastasis
Correction: Bevacizumab improved prognosis for advanced EGFR-mutant lung adenocarcinoma with brain metastasis receiving cerebral radiotherapy
2025
·
Yuanliang Zhou
, Jingchao Li
, et al.
·
Clinical & Translational Oncology
PDF
Show more works
View as search
Works count:
5
Citation count:
60
H-index:
3
I10-index:
1
Year
Topic
Type